Sanara MedTech
FORT WORTH, Texas, United States · Biotechnology, Healthcare, Health Care
Sanara MedTech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. The Company markets, distributes and develops surgical, wound and skincare products for use by physicians and clinicians in hospitals, clinics and all post-acute
Key facts
- Headquarters
- FORT WORTH, Texas, United States
- Employees
- 113
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (SMTI)
- Website
- sanaramedtech.com
- Company page
Recent activity at Sanara MedTech
- : SEC 8-K (8.01): On October 15, 2026, Sanara MedTech Inc. announced a Second Request from the FTC regarding its planned merger with MiMedx Group, Inc. under the Agreement and Plan of Merger. This request extends the waiting period mandated by the Hart-Scott-Rodino Antitrust Improvements Act, delaying the merger's completion until after the companies comply with this request. The merger will see Sanara as a wholly-owned subsidiary of MiMedx, and the completion of this transaction is contingent on the resolution of the FTC's review. Sanara continues to engage with the FTC to address the required materials for this review.
- : SEC 8-K (5.07): On September 30, 2026, Sanara MedTech Inc. held a special meeting of shareholders to vote on proposals outlined in the proxy statement filed on September 4, 2026. As of September 1, 2026, a total of 9,188,035 shares were outstanding, with 6,411,427 shares (approximately 69.78%) represented at the meeting, establishing a quorum. The meeting included critical decisions affecting the company's governance, with all voting being performed by the shareholders present or represented. The outcomes of the proposals will have strategic implications for the future direction of Sanara MedTech.
- : Sanara MedTech to merge with MiMedx Group
- : SEC 8-K (1.01): On July 29, 2026, Sanara MedTech Inc. entered into a definitive merger agreement with MiMedx Group, Inc. and its subsidiary, Mustang Merger Sub, Inc. Upon the agreement's execution, Mustang Merger Sub will merge into Sanara, making it a wholly-owned subsidiary of MiMedx Group. The merger will involve the exchange of shares, with each outstanding share of Sanara's common stock being converted into cash of $33.00 and 0.4735 shares of MiMedx common stock, totaling a value of $2.00 per share based on recent trading prices. The Board of Directors from both companies unanimously approved this merger as beneficial to their stockholders, with Sanara's shareholders set to vote on the proposal.
- : SEC 8-K (1.02): On June 2, 2026, Sanara MedTech Inc. entered into a Mutual Termination Agreement with The Catalyst Group, effectively terminating a previous Transaction Advisory Services Agreement that was established on March 20, 2023. This termination aligns with the Company's new strategic focus on soft tissue repair and bone fusion products for the surgical market. As part of the agreement, certain covenants related to indemnification and confidentiality remain in effect. The Company did not incur any fees or penalties due to this termination, suggesting a smooth transition in its advisory relationships.
- : SEC 8-K (7.01): Sanara MedTech Inc. is furnishing an investor presentation for use in meetings with investors and analysts, including during their scheduled presentation at the TD Cowen 46th Annual Health Care Conference on March 3, 2026. This presentation contains key information about the Company's priorities, strategy, and anticipated revenue for the fiscal year 2026. The presentation is included as Exhibit 99.1 and is intended to be considered alongside the Company's filings with the SEC. The disclosure relates to a communication strategy aimed to enhance investor engagement and share the Company's outlook and plans moving forward.
- : SEC 8-K (2.02): On January 23, 2026, Sanara MedTech Inc. announced preliminary financial results for the fourth quarter and full year of 2025. The press release provided insights into the company's operational performance over the past year, though specific financial figures and metrics are referenced as part of the disclosed information. This event is significant for stakeholders as it highlights trends and performance outcomes, which could influence investor perception and management strategies moving forward. The results are crucial for assessing the company's financial health and operational strategy, especially in an evolving market environment.
- : Sanara MedTech Inc. Awarded Innovative Technology Contract from Vizient for BIASURGE® Surgical Solution.
- : SEC 8-K (7.01):
- : Sanara MedTech Appoints Seth D. Yon as Chief Executive Officer
Sanara MedTech funding history
| Date | Round | Amount |
|---|---|---|
| Aug 2023 | Seed | $3.0M |
| Jul 2022 | Venture | $16.0M |
| Jun 2022 | Venture | $14.5M |
| Jul 2021 | Seed | $500K |
| Jan 2021 | Seed | $1.1M |
Leadership
- J. Carmena, Director, Executive Officer
- Robert DeSutter, Director
- Sara Ortwein, Director
- Ann Salamone, Director
- James Stuckert, Director
- Kenneth Thorpe, Director
- Ronald Nixon, Director
- J. Carmena, Director, Executive Officer
- Robert DeSutter, Director
- Ronald Nixon, Director
- Sara Ortwein, Director
- Ann Salamone, Director
Verified email and direct lines for Sanara MedTech’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Sanara MedTech files 3 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Sanara MedTech in the news
- Sanara MedTech to Participate in the Piper Sandler 37th Annual Healthcare Conference on December 3rd - Yahoo Finance (Nov 19, 2025)
- MIMEDX to Acquire Sanara MedTech - Orthopedics This Week (Jul 30, 2026)
- Form 4 SANARA MEDTECH INC. For: 16 October By Investing.com - Investing.com Nigeria (Oct 16, 2026)
- SMTI 425 & SEC Filings - Yahoo! Finance Canada (Jul 30, 2026)
Companies similar to Sanara MedTech
- Adagio Medical · Biotechnology, Healthcare, Health Care, Medical, Medical Device
- BrainScope · Biotechnology, Healthcare, Health Care, Medical, Medical Device
- Check-Cap Ltd · Biotechnology, Healthcare, Health Care, Medical, Medical Device
- Tenon Medical · Biotechnology, Healthcare, Health Care, Medical, Medical Device
- Zenflow · Biotechnology, Healthcare, Health Care, Medical, Medical Device
About Sanara MedTech: questions and answers
What does Sanara MedTech do?
Sanara MedTech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. The Company markets, distributes and develops surgical, wound and skincare products for use by physicians and clinicians in hospitals, clinics and all post-acute
Where is Sanara MedTech headquartered?
Sanara MedTech is headquartered in FORT WORTH, Texas, United States.
How many employees does Sanara MedTech have?
Sanara MedTech has about 113 employees.
Has Sanara MedTech raised funding?
Yes. Fundz has recorded 5 funding events for Sanara MedTech. The most recent, Seed of $3.0M, was in Aug 2023.
What is the latest news on Sanara MedTech?
On Oct 15, 2026, SEC 8-K (8.01): On October 15, 2026, Sanara MedTech Inc. announced a Second Request from the FTC regarding its planned merger with MiMedx Group, Inc. under the Agreement and Plan of Merger. This request extends the waiting period mandated by the Hart-Scott-Rodino Antitrust Improvements Act, delaying
Is Sanara MedTech a public company?
Yes. Sanara MedTech is publicly traded under the ticker SMTI.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy